BAM
SUPN icon

Belpointe Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Belpointe Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18
Closed -$652 – 3044
2023
Q1 		$652 Buy
+18
New +$692 ﹤0.01% 3559

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belpointe Asset Management's SUPN Position: Q2 2023 in Review

Belpointe Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 18 shares — an estimated $652 sold.

Belpointe Asset Management first reported a position in SUPN in Q1 2023 and held it in 1 quarter. The position peaked at $652 in Q1 2023. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Belpointe Asset Management reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 18 Supernus Pharmaceuticals shares in Q2 2023, an estimated $652.
  • Belpointe Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Supernus Pharmaceuticals position peaked at $652 in Q1 2023.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.